Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Leronlimab - CytoDyn

Drug Profile

Leronlimab - CytoDyn

Alternative Names: Leronlimab-PRO 140; leronlimab-PRO140; PA-14; PRO-140; Vyrologix®

Latest Information Update: 07 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Progenics Pharmaceuticals
  • Developer Albert Einstein Israelite Hospital; CytoDyn; Progenics Pharmaceuticals
  • Class Antineoplastics; Antiretrovirals; Antivirals; Hepatoprotectants; Immunotherapies; Monoclonal antibodies; Vascular disorder therapies
  • Mechanism of Action CCR5 receptor antagonists; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Triple negative breast cancer
  • Preregistration COVID 2019 infections; HIV infections
  • Phase III COVID-19 pneumonia
  • Phase II Graft-versus-host disease; Non-alcoholic steatohepatitis; Post acute COVID 19 syndrome; Solid tumours
  • Preclinical Multiple sclerosis; Stroke; Traumatic brain injuries
  • Discontinued HIV-1 infections

Most Recent Events

  • 29 Feb 2024 U.S. FDA has lifted the clinical hold on the a pre-exposure prophylaxis (PrEP) clinical trial of Leronlimab in HIV infections
  • 06 Feb 2024 Cytodyn in partnership with Albert Einstein College of Medicine and Montefiore Medical Center plans a preclinical trial for Glioblastoma in USA in 2024
  • 01 Feb 2024 Cytodyn in collaboration with Albert Einstein College of Medicine has submitted its revised HIV clinical trial protocol to the FDA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top